BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 (compounding only, no legal prescribing) into Category 1. This means BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA mulls compounding for peptides previously flagged over safety risks BioSpace FDA Peptide Reclassification 2026: What It Means for Providers Are Peptides coming off of the FDA Category 2 list? A legal breakdown Holt Law